ESR1 and breast carcinoma: In this study, the cytotoxicity of MMV652103 was tested in several breast cancer cell lines with different receptor status and results show that MMV652103 was most potent in the ER+ cell lines, MCF7 and T47D, where it exhibited an average IC50 of 2.5 μM.